Impact of PSA Screening on Prostate Cancer Outcomes in Korea

A comprehensive cohort study conducted in Korea from 2006 to 2018 has revealed significant benefits associated with sustained prostate-specific antigen (PSA) screening for prostate cancer (PCa). The research, which included 5,437 men diagnosed with PCa, demonstrated that increased PSA screening correlates with earlier detection of localized tumors and improved survival rates.

Long-Term PSA Screening Improves Prostate OutcomesBMC Cancer JournalNoninvasive Urine Biomarkers Detect Bladder Cancer

The study found that the utilization of PSA screening increased from 46.4% in 2006 to 63.1% in 2018. Patients diagnosed through PSA screening exhibited significantly better disease profiles, with a higher proportion of organ-confined tumors and fewer metastatic cases at diagnosis. Specifically, PSA-detected patients had a 54% reduction in the risk of dying from prostate cancer compared to those diagnosed based on symptoms. This aligns with findings from other studies indicating that higher PSA screening rates are associated with lower rates of metastatic disease.

Long-Term PSA Screening Improves Prostate OutcomesBMC Cancer JournalNoninvasive Urine Biomarkers Detect Bladder CancerBreast Cancer Health, Prevention, and ScreeningRisk of breast cancer death 40% higher if first mammogram missed

Unlike the United States, where the 2012 USPSTF recommendation against routine PSA screening led to a decline in screening rates and an increase in advanced disease presentations, Korea maintained high screening rates. This divergence highlights the impact of health policy and practice differences, as Korea lacks national guidelines for PSA screening, relying instead on opportunistic screening through annual health check-ups.

BMC Cancer JournalLong-Term PSA Screening Improves Prostate OutcomesWomen who skip first mammogram more likely to die of breast cancerRisk of breast cancer death 40% higher if first mammogram missed

The study underscores the importance of PSA screening in facilitating early cancer detection and reducing the incidence of advanced disease. It suggests that sustained PSA screening can lead to a forward stage migration, where more localized and treatable cancers are detected. The findings advocate for the optimization of screening programs to enhance early detection while minimizing the risks of overdiagnosis and overtreatment.

Long-Term PSA Screening Improves Prostate OutcomesBMC Cancer JournalWomen who skip first mammogram more likely to die of breast cancerRisk of breast cancer death 40% higher if first mammogram missed

Despite the positive outcomes associated with PSA screening, the study acknowledges several limitations. It is a retrospective analysis from a single tertiary center, which may introduce referral bias and limit generalizability. Additionally, the study did not include treatment data, which could influence survival outcomes. The researchers also noted the potential for lead-time bias, where earlier detection may artificially inflate survival rates without altering the natural course of the disease.

BMC Cancer Journal

The authors of the study emphasize the need for a balanced approach to PSA screening, advocating for individualized screening strategies that consider patient risk factors. They call for careful re-expansion of screening programs to reverse unfavorable trends in advanced PCa, highlighting that effective screening can significantly reduce cancer-specific mortality.

BMC Cancer JournalLong-Term PSA Screening Improves Prostate OutcomesWomen who skip first mammogram more likely to die of breast cancerRisk of breast cancer death 40% higher if first mammogram missed

• “The lack of mortality reduction in the PLCO trial has been largely attributed to methodological issues (such as contamination by opportunistic screening in the control arm), and our findings lend support to the notion that effective PSA screening – when applied in an organized or opportunistic but widespread manner – can reduce cancer-specific mortality by preventing advanced disease.” — Kim, J.K., Lead Researcher

BMC Cancer Journal

• “Essentially, the earlier detection and treatment facilitated by screening likely prevented a number of cancers from progressing to lethal metastatic stages.” — Park, M.U., Co-Author

BMC Cancer Journal

• “In essence, the grading system change has made Gleason 6 a rarer entity by design, concentrating more cancers into Gleason 7; this underscores that not all observed grade trends are due to screening per se, but also to how we classify disease.” — Lee, D., Co-Author

BMC Cancer Journal

This study provides robust evidence that sustained PSA screening is associated with improved prostate cancer outcomes in Korea, emphasizing the need for continued monitoring and optimization of screening practices. As healthcare systems globally grapple with the balance between early detection and minimizing harms, the findings reinforce the role of PSA screening as a critical tool in reducing prostate cancer mortality.

Long-Term PSA Screening Improves Prostate OutcomesBMC Cancer JournalWomen who skip first mammogram more likely to die of breast cancerRisk of breast cancer death 40% higher if first mammogram missed